NCT02143804 2026-04-02
exBOND
CG Oncology, Inc.
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT02555397 2024-10-10
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Henry Ford Health System
Phase 1 Completed
NCT04097002 2023-10-31
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
Orca Therapeutics B.V.
Phase 1/2 Unknown
NCT04374240 2021-11-03
AdUP
University of Birmingham
Phase 1 Completed
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT03384316 2020-09-09
Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02654938 2017-09-20
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Panacela Labs LLC
Phase 1 Completed
NCT02844699 2017-09-20
A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer
Panacela Labs LLC
Phase 1/2 Unknown
NCT00625430 2011-07-11
FP253-GDEPT
Biotech Equity Partners Pty Ltd
Phase 1 Unknown
NCT00109655 2008-10-03
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
Cell Genesys
Phase 1 Unknown